Markers of Executive Attention Development in Preschoolers (MEDiATE)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Caen, France, 14032
- Recruiting
- Comete U1075 Inserm Unicaen
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Normal schooling
- Parental consent
Exclusion Criteria:
- Psychotropic drug
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Term
|
EEG
|
|
Preterm
|
EEG
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Amplitude in µV of EEG changes relative to baseline when expected stimulus is omitted in a tactile stimulation sequence
Time Frame: at 4 years old
|
at 4 years old
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2020-A01503-36
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Attention Deficit Disorder
-
NCT07541820Active, not recruitingAttention-Deficit Hyperactivity Disorder | Attention-Deficit Hyperactivity Disorder Symptoms
-
NCT07217977Enrolling by invitationAttention Deficit Disorder With Hyperactivity (ADHD) | Attention Deficit Disorder (ADD)
-
NCT07633275RecruitingAttention-Deficit/Hyperactivity Disorder
-
NCT05924594SuspendedPhase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301ADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit Hyperactivity
-
NCT07592390RecruitingAttention-Deficit/Hyperactivity Disorder (ADHD)
-
NCT07565402RecruitingAdult Attention Deficit Hyperactivity Disorder
-
NCT07300956Not yet recruitingAttention-Deficit/Hyperactivity Disorder (ADHD)
-
NCT07253441CompletedAttention Deficit Disorder With Hyperactivity
-
NCT07203092RecruitingAttention Deficit Hyperactivity Disorder
Clinical Trials on EEG
-
NCT06025201RecruitingHealthy | Chronic Low-back Pain
-
NCT02413177Completed
-
NCT05977439RecruitingHealthy | Depression - Major Depressive Disorder
-
NCT07592169Not yet recruitingSchizoaffecitve Disorder | SCHIZOPHRENIA 1 (Disorder)
-
NCT03856775CompletedNon-convulsive Seizures
-
NCT05380921Enrolling by invitation
-
NCT01591408CompletedPTSD | Anxiety | Trauma | Sleep Disorders
-
NCT01518426Completed
-
NCT02292368CompletedHead and Neck Cancer